Eli Lilly has launched Foundayo (orforglipron), the first FDA-approved oral GLP-1 pill for weight loss that can be taken anytime without food or water restrictions. Approved on April 1, 2026, Foundayo helps adults with obesity or overweight lose weight alongside diet and exercise, with clinical trials showing an average loss of 27 pounds at the highest dose. It is available via LillyDirect home delivery, telehealth providers, and retail pharmacies across the U.S., starting at $25 per month with insurance or $149 for self-pay. Foundayo also showed benefits in reducing cardiovascular risk markers, but carries warnings including potential thyroid tumors and common gastrointestinal side effects. This launch expands accessible obesity treatment options in the U.S.
